Anne McLaren Lecture
Can reformed communication save patients from harm?
Professor Marie Lindquist Director of the Uppsala Monitoring Centre, will give this year’s Anne McLaren Lecture.
Too many patients are harmed by their therapy; too many patients fail to get full benefit from their treatment; too many of those in need of medical care do not have access to it. In a world often influenced as much by fake news, superstition and conspiracy theories as by evidence and fact, where expert opinion may be doubted or rejected, how can we reach the aspirational vision of improved patient safety? What is the nature of the relationships and communications that might help us recover lost ground and make progress?
The OIBC Anne McLaren Lecture is held in conjunction with Kellogg College and the Trustees of the Oxford International Biomedical Centre. Dr Anne McLaren, DBE, Hon DSc, FRS (1927-2007) was a Trustee of the Oxford International Biomedical Centre. Her distinction as an experimental scientist in the field of mammalian embryology was matched by her concern for the ethical and legal consequences of in vivo fertilisation (IVF) and other clinical advances in human embryology. She is commemorated in Anne McLaren House at Kellogg College.
Refreshments will be served from 17:00 and the lecture will begin at 17:30. All are welcome and admission is free. Booking is essential.
Marie Lindquist is the Director and CEO of Uppsala Monitoring Centre (UMC), a self-funded non-profit foundation based in Sweden. UMC is a Collaborating Centre to the World Health Organization (WHO), managing the technical and operational activities of the WHO Programme for International Drug Monitoring – a global network of national pharmacovigilance centres in more than 130 countries.
Marie has a Masters in Pharmacy and a Doctorate in Medical Sciences, and has published research in many areas of pharmacovigilance. She also has extensive hands-on experience in signal detection methodology, data management, classifications and terminologies, and is actively involved in international standardisation efforts and global pharmacovigilance development initiatives.
This lecture will be photographed and videod. If you do not wish to appear in the photographs or footage, please let the photographer or videographer know. Should you have any further queries, please contact email@example.com